オプションチェーンは、Lifevantageの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Lifevantageの市場センチメントを評価します。.

Lifevantage (NASDAQ:LFVN) 株価情報, オプションチェーン

Lifevantage

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Lifevantage Corp

WIIM

LFVN

LifeVantage shares are trading higher after the company reported preliminary Q2 revenue and raised its FY25 revenue guidance.

News

Guidance

LifeVantage Reports Preliminary Q2 Revenue of $67.5M vs $51.45, Up 31% YoY and 43% Sequentially, Raises FY25 Revenue Guidance to $235M-$245M vs Prior $200M-$210M (Est. $204.3M)

As of Jan. 6, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Oil-Dri Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>)</h3>
<ul>
<li>On Dec. 9, Oil-Dri reported a year-over-year increase in first-quarter financial results. Daniel S. Jaffee, President and Chief Executive Officer, stated, &#8220;I am happy to report that our fiscal year 2025 is off to a very positive start as we have once again achieved record results for consolidated net sales, gross profit, and net income in the first quarter." The company's stock surged around 29% over the past month and has a <a href="https://www.benzinga.com/quote/ODC">52-week high of $93.00</a>.</li>
<li>RSI Value: 91.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ODC Price Action: Shares of Oil-Dri Corporation of America fell 48.9% to close at $43.78 on Friday.</li>
</ul>
<h3 class="wp-block-heading">LifeVantage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>)</h3>
<ul>
<li>On Dec. 19, Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26. The company's stock gained around 22% over the past month and <a href="https://www.benzinga.com/quote/LFVN">has a 52-week high</a> of $19.06.</li>
<li>RSI Value: 70.4</li>
<li>LFVN Price Action: Shares of LifeVantage gained 0.7% to close at $17.79 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42810054/this-analyst-with-85-accuracy-rate-sees-around-16-downside-in-tesla-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

Top 2 Defensive Stocks That May Crash In Q1

As of Dec. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Paranovus Entertainment Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>)</h3>
<ul>
<li>On Sept. 13, Paranovus Entertainment Technology filed for offering of 60 million Class A ordinary shares offered by selling shareholders. The company has a <a href="https://www.benzinga.com/quote/PAVS">52-week high of $2.97</a>.</li>
<li>RSI Value: 84.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAVS Price Action: Shares of Paranovus Entertainment gained 1.4% to close at $1.42 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Duckhorn Portfolio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>)</h3>
<ul>
<li>On Dec. 5, Duckhorn Portfolio posted in-line quarterly earnings. &#8220;We are pleased to begin fiscal 2025 with strong financial performance. Our growth continues to outpace the industry as our teams remain focused on advancing our strategic initiatives,&#8221; said Deirdre Mahlan, President, CEO and Chairperson. &#8220;We believe our distinctive brands, operational excellence and market-leading performance leave us well positioned to deliver long-term growth and profitability.&#8221; The company's stock gained around 48% over the past six months and <a href="https://www.benzinga.com/quote/NAPA">has a 52-week high</a> of $11.10.</li>
<li>RSI Value: 76.78</li>
<li>NAPA Price Action: Shares of Duckhorn Portfolio climbed 0.1% to close at $11.09 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">LifeVantage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>)</h3>
<ul>
<li>On Dec. 19, Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26. The company's stock gained around 37% over the past month and has a <a href="https://www.benzinga.com/quote/LFVN">52-week high</a> of $18.41.</li>
<li>RSI Value: 71.65</li>
<li>LFVN Price Action: Shares of LifeVantage jumped 15.5% to close at $17.73 on Thursday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a></li>
</ul>

NAPA

PAVS

Top 3 Risk Off Stocks That May Collapse This Month

Lifevantage shares are trading higher after Lake Street initiated coverage on the stock with a Buy rating and announced a price target of $26.

Lake Street analyst Brooks O'Neil initiates coverage on Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) with a Buy rating and announces Price Target of $26.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Lifevantage with Buy Rating, Announces Price Target of $26

<a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a>

Biotech

General

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

TERN

VANI

VKTX

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

<a href="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf" title="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf">https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf</a>

'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape

Disclosed in the latest SEC filing, a significant insider purchase on November 12, involves Darwin Lewis, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>).
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000132//Archives/edgar/data/849146/000084914624000132/0000849146-24-000132-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled that Lewis made a notable purchase of 7,819 shares of Lifevantage, valuing at $105,009.
Lifevantage shares are trading up 0.29% at $13.78 at the time of this writing on Wednesday morning.
<h3>Delving into Lifevantage's Background</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Breaking Down Lifevantage's Financial Performance</h3>
Revenue Challenges: Lifevantage's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.08%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a high gross margin of 79.9%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.91, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio, surpassing industry averages at 17.77, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Massive Insider Trade At Lifevantage

In a recent SEC filing, it was revealed that Garry P. Mauro, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), made a noteworthy insider purchase on November 12,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000133//Archives/edgar/data/849146/000084914624000133/0000849146-24-000133-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Mauro purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
The latest update on Wednesday morning shows Lifevantage shares up by 0.29%, trading at $13.78.
<h3>Delving into Lifevantage's Background</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Breaking Down Lifevantage's Financial Performance</h3>
Revenue Growth: Lifevantage's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -8.08%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 79.9%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.91 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 17.77, Lifevantage demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of Lifevantage Makes $105K Buy

On November 12, Rajendran Anbalagan, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000134//Archives/edgar/data/849146/000084914624000134/0000849146-24-000134-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Anbalagan purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
As of Wednesday morning, Lifevantage shares are up by 0.29%, currently priced at $13.78.
<h3>Unveiling the Story Behind Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: Financial Performance Dissected</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 79.9%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 42.94 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.91 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 17.77, Lifevantage demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: Rajendran Anbalagan Shows Faith, Buying $105K In Lifevantage Stock

It was revealed in a recent SEC filing that Michael Beindorff, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) made a noteworthy insider purchase on November 12,.
What Happened: Beindorff demonstrated confidence in Lifevantage by purchasing 7,819 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000135//Archives/edgar/data/849146/000084914624000135/0000849146-24-000135-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the transaction is $105,009.
The latest market snapshot at Wednesday morning reveals Lifevantage shares up by 0.29%, trading at $13.78.
<h3>All You Need to Know About Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Key Indicators: Lifevantage's Financial Health</h3>
Decline in Revenue: Over the 3 months period, Lifevantage faced challenges, resulting in a decline of approximately -8.08% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 79.9%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 42.94 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.91 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio stands at 17.77, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Board Member Makes $105K Stock Purchase

Dayton Judd, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported an insider buy on November 12, according to a new SEC filing. 
What Happened: Judd's recent purchase of 7,819 shares of Lifevantage, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000136//Archives/edgar/data/849146/000084914624000136/0000849146-24-000136-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, reflects confidence in the company's potential. The total transaction value is $105,009.
The latest market snapshot at Wednesday morning reveals Lifevantage shares up by 0.29%, trading at $13.78.
<h3>All You Need to Know About Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: A Financial Overview</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 42.94 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.91, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio stands at 17.77, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dayton Judd Of Lifevantage Shows Optimism, Buys $105K In Stock

It was revealed in a recent SEC filing that Raymond B Greer, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) made a noteworthy insider purchase on November 12,.
What Happened: Greer's recent purchase of 7,819 shares of Lifevantage, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000137//Archives/edgar/data/849146/000084914624000137/0000849146-24-000137-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, reflects confidence in the company's potential. The total transaction value is $105,009.
Monitoring the market, Lifevantage's shares up by 0.29% at $13.78 during Wednesday's morning.
<h3>Unveiling the Story Behind Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage's Economic Impact: An Analysis</h3>
Revenue Challenges: Lifevantage's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.08%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: Lifevantage's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 42.94.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.91 is lower than the industry average, implying a discounted valuation for Lifevantage's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio, surpassing industry averages at 17.77, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: Raymond B Greer Shows Faith, Buying $105K In Lifevantage Stock

On November 12, a substantial insider purchase was made by Cynthia Latham, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000138//Archives/edgar/data/849146/000084914624000138/0000849146-24-000138-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Latham purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
During Wednesday's morning session, Lifevantage shares up by 0.29%, currently priced at $13.78.
<h3>Discovering Lifevantage: A Closer Look</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: Financial Performance Dissected</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 79.9%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average. The company faced challenges with a current EPS of 0.15. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.91, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 17.77, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

105K Reasons To Be Bullish On Lifevantage Stock

Lifevantage shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) affirms FY2025 Adj EPS guidance from $0.70-0.80 to $0.70-0.80 vs $0.72 analyst estimate. Affirms FY2025 sales outlook from $200.00 million-210.00 million to $200.00 million-210.00 million vs $204.80 million estimate.

Lifevantage Affirms FY2025 Adj EPS Guidance from $0.70-0.80 to $0.70-0.80 vs $0.72 Est; Affirms FY2025 Sales Guidance from $200.00M-210.00M to $200.00M-210.00M vs $204.80M Est

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 15.38 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $47.214 million which missed the analyst consensus estimate of $49.800 million by 5.19 percent. This is a 8.08 percent decrease over sales of $51.364 million the same period last year.

Earnings

Earnings Misses

Lifevantage Q1 2025 Adj. EPS $0.15, Inline, Sales $47.214M Miss $49.800M Estimate

LifeVantage Corporation Released Encouraging Results From A Human Clinical Trial On Its New MindBody GLP-1 System. The Results Included A 140% Increase In GLP-1 Levels In The Body Leading To An Average Weight Loss of 9 Pounds In 8 Weeks And Up To 25 Pounds In 12 Weeks

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-10-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Lifevantage will report an earnings per share (EPS) of $0.15.
Anticipation surrounds Lifevantage's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.07, leading to a 11.8% drop in the share price on the subsequent day.
Here's a look at Lifevantage's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
<td>0.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-12.0%</td>
<td>8.0%</td>
<td>-9.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking Lifevantage's Stock Performance</h3>
Shares of Lifevantage were trading at $14.09 as of October 25. Over the last 52-week period, shares are up 83.87%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LFVN/earnings">To track all earnings releases for Lifevantage visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Lifevantage's Earnings

LifeVantage Corp ( ($LFVN) ) has realeased its Q1 earnings. Here is a breakdown of the information LifeVantage Corp presented to its investors. Lif...

LifeVantage Reports Q1 Fiscal 2025 Financial Results

LifeVantage (LFVN) Corporation is elevating lip care this holiday season by bringing back the exclusive TrueScience TruePout Hydrating Lip Oil to t...

LifeVantage returns TrueScience Hydrating Lip Oil to U.S. Market

What to expect in the food sector in 2025

Revenue of approximately $67.5 million, an increase of 31% from the prior year period, and up 43% sequentially from the first fiscal quarter; Activ...

LifeVantage sees Q2 revenue $67.5M, up 31% vs. last year

The Company now expects revenue in the range of $235 million to $245 million in fiscal 2025 compared to prior revenue guidance of $200 million to $...

LifeVantage raises FY25 revenue view $235M-$245M from $200M-$210M

Lake Street Remains a Buy on LifeVantage (LFVN)

LifeVantage expects Q2 revenue of about $67.5M, raises FY25 sales guidance

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – LifeVantage (LFVN) up 33% after initiating Q2 and FY25 g...

Morning Movers: AngioDynamics jumps following results and guidance raise

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shell (SHEL) trimmed its LNG pro...

Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz

LifeVantage soars after seeing a sales boost from its GLP-1 product

AAPL

ACCD

ALLY

ALTM

ANGO

BRFS

CDXC

COLL

CVNA

FLUT

FRPT

HALO

HELE

INMD

IONQ

LWAY

MHGVY

MSFT

NVDA

PROF

QUBT

RGTI

SANA

SHEL

SNPS

TWLO

VITL

Health Care

Press Releases

LifeVantage to Announce First Quarter Fiscal Year 2025 Results on October 29, 2024

LifeVantage to Participate at the LD Micro Main Event XVII

LifeVantage Reports Full Clinical Results Including Average of 140% Increase in GLP-1 with the MindBody GLP-1 System™Ω

Dividends

LifeVantage Declares Quarterly Dividend

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025

LifeVantage to Participate at the Sidoti Micro Cap Conference

LifeVantage Unveils Lip Care Favorite Back for Cyber Monday

LifeVantage to Participate in the Water Tower Fireside Chat Series

LifeVantage to Participate in the 27th Annual ICR Conference

LifeVantage Announces Preliminary Second Quarter Revenue Results and Raises Fiscal 2025 Revenue Guidance

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Lifevantage

Lifevantage (LFVN) オプション

Lifevantage (NASDAQ:LFVN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル